Consolidated Statements of Stockholders’ Equity (Unaudited) - USD ($) $ in Thousands	Total	Common shares	Treasury Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income / (Loss)	Retained Earnings / (Deficit)
Balance, beginning of period (in shares) at Jun. 30, 2024		17,017,000
Balance, beginning of period at Jun. 30, 2024	$ 165,799	$ 2	$ (25,367)	$ 210,200	$ (7,913)	$ (11,123)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	27,268					27,268
Foreign currency translation adjustments	851				851
Changes in fair value of cash flow hedges	571				571
Purchase of treasury shares (in shares)		(3,890,000)
Purchase of treasury shares	(76,292)	$ (1)	(76,291)
Issuance of common shares (in shares)		245,000
Issuance of common shares	3,534			3,534
Stock-based compensation expense	2,450			2,450
Balance, end of period (in shares) at Mar. 31, 2025		13,372,000
Balance, end of period at Mar. 31, 2025	124,181	$ 1	(101,658)	216,184	(6,491)	16,145
Balance, beginning of period (in shares) at Dec. 31, 2024		13,182,000
Balance, beginning of period at Dec. 31, 2024	108,937	$ 1	(101,606)	212,116	(7,250)	5,676
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	10,469					10,469
Foreign currency translation adjustments	374				374
Changes in fair value of cash flow hedges	385				385
Purchase of treasury shares	(52)		(52)
Issuance of common shares (in shares)		190,000
Issuance of common shares	2,809			2,809
Stock-based compensation expense	1,259			1,259
Balance, end of period (in shares) at Mar. 31, 2025		13,372,000
Balance, end of period at Mar. 31, 2025	$ 124,181	$ 1	(101,658)	216,184	(6,491)	16,145
Balance, beginning of period (in shares) at Jun. 30, 2025	13,357,990	13,358,000
Balance, beginning of period at Jun. 30, 2025	$ 134,309	$ 1	(103,338)	218,241	(6,336)	25,741
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	37,584					37,584
Foreign currency translation adjustments	(2,704)				(2,704)
Changes in fair value of cash flow hedges	(4,283)				(4,283)
Purchase of treasury shares (in shares)		(310,000)
Purchase of treasury shares	(10,108)		(10,108)
Issuance of common shares (in shares)		455,000
Issuance of common shares	3,883	$ 1		3,882
Shares withheld related to net share settlement of equity awards (in shares)		(67,000)
Shares withheld related to net share settlement of equity awards	(2,369)			(2,369)
Stock-based compensation expense	$ 4,471			4,471
Balance, end of period (in shares) at Mar. 31, 2026	13,435,541	13,436,000
Balance, end of period at Mar. 31, 2026	$ 160,783	$ 2	(113,446)	224,225	(13,323)	63,325
Balance, beginning of period (in shares) at Dec. 31, 2025		13,440,000
Balance, beginning of period at Dec. 31, 2025	154,515	$ 2	(108,893)	223,927	(10,521)	50,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	13,325					13,325
Foreign currency translation adjustments	(1,123)				(1,123)
Changes in fair value of cash flow hedges	(1,679)				(1,679)
Purchase of treasury shares (in shares)		(140,000)
Purchase of treasury shares	(4,553)		(4,553)
Issuance of common shares (in shares)		200,000
Issuance of common shares	467			467
Shares withheld related to net share settlement of equity awards (in shares)		(64,000)
Shares withheld related to net share settlement of equity awards	(2,261)			(2,261)
Stock-based compensation expense	$ 2,092			2,092
Balance, end of period (in shares) at Mar. 31, 2026	13,435,541	13,436,000
Balance, end of period at Mar. 31, 2026	$ 160,783	$ 2	$ (113,446)	$ 224,225	$ (13,323)	$ 63,325